Evidence map›Paper›PMID 24317955›Full record

ArticleAnnals of behavioral medicine : a publication of the Society of Behavioral Medicine2014

Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus.

Jae M Sevelius, Enzo Patouhas, Joanne G Keatley, Mallory O Johnson

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of behavioral medicine : a publication of the Society of Behavioral Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04050371 (I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones), which is not on this map. Cited by 215 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
215citing papers in PubMed, 5 pooled it
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04050371 phase4completednot on this mapstarted 2017, after this paper: background citation

I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2018Enrolled48ConditionsHIV Prevention, Transgender HealthArms200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
3 · Its place in the literature

Who cites it

215 citing papers in PubMed, 5 syntheses or guidelines pooled it, 348 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021
    Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

155 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jae M SeveliusDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA, jae.sevelius@ucsf.edu.
Enzo Patouhas
Joanne G Keatley
Mallory O Johnson
University of California, San Francisco · USSan Francisco AIDS Foundation · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Culturally Relevant HIV Prevention for High-Risk WomenK08MH085566 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEVELIUS, JAE M. · 2009 to 2013
$836k
Dyadic Processes in the Patient-Provider RelationshipK24MH087220 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSON, MALLORY O · 2009 to 2013
$771k
NIAID NIH HHS P30 AI027763NIMH NIH HHS K08 MH085566NIMH NIH HHS K08MH085566NIMH NIH HHS K24 MH087220NIMH NIH HHS K24MH087220
6 · The paper itself

Abstract

backgroundTransgender women have 49 times the odds of human immunodeficiency virus (HIV) infection compared to other groups, yet they are disproportionately underserved by current treatment efforts. PURPOSE: This study aimed to examine culturally unique barriers and facilitators to engagement and retention in HIV care and strengthen efforts to mitigate health disparities, guided by the Models of Gender Affirmation and Health Care Empowerment.

methodsThrough 20 interviews and five focus groups (n = 38), transgender women living with HIV discussed their experiences and life contexts of engagement in and adherence to HIV care and treatment.

resultsOur participants faced substantial challenges to adhering to HIV care and treatment, including avoidance of healthcare due to stigma and past negative experiences, prioritization of hormone therapy, and concerns about adverse interactions between antiretroviral treatment for HIV and hormone therapy. Receiving culturally competent, transgender-sensitive healthcare was a powerful facilitator of healthcare empowerment.

conclusionsRecommendations are offered to inform intervention research and guide providers, emphasizing gender affirming HIV care that integrates transition-related healthcare needs.

Indexed as

Healthcare DisparitiesHealth Services AccessibilityTransgender PersonsAdultAgedFemaleFocus GroupsHIV InfectionsHumansMaleMiddle AgedPatient ComplianceSocial StigmaWomen

Identifiers

PMID24317955
PMCPMC3925767
OpenAlexW2009747821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.